Back to Results
First PageMeta Content
Boxed warning / Food and Drug Administration / Hazards / Pharmaceutical industry / Medical error / Patient safety / Medicine / Health / Piperazines


BLINCYTO™ (blinatumomab) Drug Class: Bispecific CD19-directed CD3 T-cell engager Amgen Inc.
Add to Reading List

Open Document

File Size: 516,65 KB

Share Result on Facebook

City

Philadelphia / Reference / /

Company

Amgen Inc. / MBE / /

IndustryTerm

home healthcare pharmacists / home healthcare oncology nurses / healthcare / healthcare providers / /

MedicalCondition

convulsions / headache / nausea / disorientation / acute lymphoblastic leukemia / encephalopathy / speech disorders / balance disorders / cytokine release syndrome / hypotension / /

MedicalTreatment

medication errors / /

Organization

National Association / BLINCYTO administration / American Society of Health System Pharmacists / American Society of Hematology / REMS FDA / FDA / Hematology Oncology Pharmacy Association / Home Health Nurses Association / American Society of Clinical Oncology / American Pharmacists Association / Practitioner Society for Hematology and Oncology / Oncology Nursing Society / /

Person

Isma Benattia / /

/

Position

Pharmacist / nurse / physician / Vice President / Global Patient Safety BLINCYTO™ / /

Product

Information Medication / Sterile Water for Injection / /

PublishedMedium

the PI / Medication Guide / /

URL

www.fda.gov/medwatch / www.blincytorems.com / /

SocialTag